Respivert Limited

Topivert Pharma Limited

Albert Einstein College of Medicine

Victoria Link Limited

Alistair Ian Longshaw

Stuart Thomas Onions

John King-Underwood

Kazuhiro Ito

Catherine Elisabeth Charron

Jennifer Diane Venable

Euan Alexander Fraser Fordyce

Alex Herman Copmans

Rudy Broeckx

Walter Filliers

Iain Walters

Vern L Schramm

Peter Charles Tyler

Gary Brian Evans

Peter John Murray

Jonathan Gareth Williams

Lorna Duffy

David Michael Adrien Taddei

Alex Copmans

A compound has the following formula: The compound is a p38 MAP kinase inhibitor. The compound and its pharmaceutically acceptable salts can be used for treatment of conditions, such as inflammatory diseases.

Inhibitor of p38 MAP kinase

There are provided compounds of formula (I) as defined in the specification which are p38 MAP kinase inhibitors for use as medicaments for the treatment inter alia of inflammatory diseases. 

Pyrazolyl-ureas as kinase inhibitors

There are provided compounds of formula (I) which are inhibitors of the family of p38 mitogen-activated protein kinase enzymes, and to their use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as asthma and COPD.

1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as P38 MAP knase inhibitors

A dry powder pharmaceutical formulation for inhalation including a compound of formula (I): that is 1-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)-3-(4-((2-((6-ethylpyrazin-2-yl)amino)pyridin-4-yl)methoxy)naphthalen-1-yl)urea or a pharmaceutically acceptable salt thereof, including all stereoisomers, tautomers and isotopic derivatives thereof; and lactose as a topically acceptable diluent. An inhaler device containing the dry powder pharmaceutical formulation is also described.

There is provided a compound of formula (I) which is an inhibitor of the family of p38 mitogen-activated protein kinase enzymes, and to its use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as asthma and COPD.

1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-i-yl) ureas as P38 mapkinase inhibitors

There are provided compounds of formula (I) shown below as defined in the specification which are p38 MAP kinase inhibitors for use as medicaments for the treatment inter alia of inflammatory diseases. 

Pyrazolyl ureas as kinase inhibitors

1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-I-yl) ureas as P38 mapkinase inhibitors

1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as p38 MAP kinase inhibitors

Inhibitor of p38 map kinase

The present invention relates to 3-hydroxypyrrolidine compounds of the general formula (1) which are inhibitors of 5'-methylthioadenosine phosphorylase or 5&#x2032;-methylthioadenosine nucleosidase. The invention also relates to the use of these compounds in the treatment of diseases or conditions in which it is desirable to inhibit 5&#x2032;-methylthioadenosine phosphorylase or 5&#x2032;-methylthioadenosine nucleosidase including cancer, and to pharmaceutical compositions containing the compounds.

3-hydroxypyrrolidine inhibitors of 5'-methylthioadenosine phosphorylase and nucleosidase

There are provided compounds of formula (I) as defined in the specification, which are p38 MAP kinase inhibitors for use as medicaments for the treatment inter alia of inflammatory diseases. 

1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl) ureas as P38 MAP knase inhibitors

A compound of formula (XV):  wherein Rrepresents an amino group, a protected amino group or nitro group; or a salt thereof. The compound is a p38 MAP kinase inhibitor. The compound and its pharmaceutically acceptable salts can be used for treatment of conditions, such as inflammatory diseases.

Growing community of inventors

Nottingham, United Kingdom

Alistair Ian Longshaw